37 results
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
19 Apr 24
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
5:16pm
allow the Company additional time to regain such compliance. However, there can be no assurance that the Panel will grant the Company's request
424B5
qq6tdhyl
22 Mar 24
Prospectus supplement for primary offering
10:24am
6-K
EX-10.1
0vmbcrbj
21 Mar 24
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
5:14pm
6-K
EX-99.2
ljhgbrp
6 Dec 23
Unaudited Interim Condensed Financial Statements
4:44pm
6-K
EX-99.1
us6wfpl1dli2d7mx2n9
6 Dec 23
Unaudited Interim Condensed Financial Statements
4:44pm
6-K
EX-99.3
lepc11bzlb 8wbj20
8 Dec 22
Report of Foreign Private Issuer
4:30pm
F-3
xtgn bxryz3t5gv71hv2
6 Dec 22
Shelf registration (foreign)
4:41pm
6-K
EX-99.1
r53yjh
11 Oct 22
Unaudited Interim Condensed Financial Statements
5:20pm
6-K
EX-99.2
truckdmth 2ypuu
6 Oct 22
Report of Foreign Private Issuer
4:01pm
6-K
EX-99.2
fucv95cc2j5pec417m3
3 Oct 22
Report of Foreign Private Issuer
8:51am
F-1
55x3b5 jrspi446cvf
10 Jun 22
Registration statement (foreign)
4:43pm
6-K
EX-10.1
j6y03vwpo0
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
424B5
acn46jr
14 Apr 22
Prospectus supplement for primary offering
4:48pm
6-K
EX-1.1
zl46xesfogkgkh4rb
4 Mar 22
Report of Foreign Private Issuer
4:02pm